TherapeuticsMD turns small Q2 profit on royalties and one-offs; Mayne litigation clouds outlook

TherapeuticsMD, Inc. (NYSE: TXMD) - Quick internal read

All amounts below are in thousands of USD and per the company's Form 10-Q for the quarter ended June 30, 2025.

What's happening inside: the company has fully transitioned to a royalty model after the Mayne Transaction. Operations are lean (one employee), revenue is royalty-driven and concentrated, cash is modest but improved, and the business is embroiled in legal disputes with its key licensee, Mayne Pharma, which creates material uncertainty.

Key points & stats
* Cash and cash equivalents (June 30, 2025): $6,069
* Total assets: $38,504; Stockholders' equity: $27,292; Accumulated deficit: $(951,924)
* Royalty receivable - current: $3,743; long-term: $14,840 (total $18,583)
* License revenue - Q2 2025: $952 (up from $234 in Q2 2024); YTD 2025: $1,345 vs $547 YTD 2024
* Net income (loss) - Q2 2025: $551 (EPS $0.05); Q2 2024: $(1,090) (EPS $(0.09))
* Six months ended June 30, 2025: Net loss $(102) vs $(1,824) in 2024
* Operating expenses - Q2 2025: total $1,647 (SG&A $1,551); Q2 2024: $3,023 (includes $1,261 impairment)
* Loss from operations - Q2 2025: $(695); Q2 2024: $(2,789)
* Other income, net (Q2 2025): $1,240 (sublease $376; miscellaneous $866) - a key driver of quarterly profitability
* Net cash provided by continuing operating activities (YTD 2025): $1,080 (vs $1,224 YTD 2024)

Positive aspects (income statement & finance)
* License revenue growth: Q2 revenue increased materially (from $234 to $952) and YTD revenue up ~146% year-over-year - shows improved royalty receipts.
* Lower operating expenses in 2025 vs 2024 - the large impairment in 2024 did not repeat, improving operating loss materially.
* Q2 turned to net income ($551) driven by higher license revenue plus significant other income (settlement and sublease items).
* Cash generation from continuing operations remains positive (YTD $1,080), and cash balance grew to $6,069 at quarter end.

Negative aspects / risks (income statement & business)
* Profitability is fragile and aided by one-time or non-recurring items (miscellaneous settlements, sublease gains). Core operating loss persists: Q2 operating loss $(695).
* Revenue is small in absolute terms (Q2 license revenue $952) and concentrated: 100% of license revenue comes from Mayne, Theramex and Knight - high counterparty concentration risk.
* Large accumulated deficit remains ($(951,924)) and equity base is modest ($27,292).
* Ongoing legal disputes with Mayne Pharma (company sued Mayne 4/8/2025; Mayne countersued 5/30/2025). The company has not accrued additional liabilities because loss ranges are unestimable - this is a material but uncertain exposure.
* Going concern language: management cites substantial doubt about ability to continue for 12 months without additional financing; may need equity or debt that would dilute shareholders.
* Royalties and future revenue depend on Mayne's commercial performance and patent/enforcement outcomes (Paragraph IV challenges from generic filers). Royalty rates step down dramatically on generic entry or patent expiry.

Bottom line / near-term outlook
TherapeuticsMD has stabilized some cash flow and booked higher royalties in Q2, but its results are still small and heavily dependent on a few counterparties and on legal outcomes with Mayne Pharma and generic challengers. The company shows improving operating trends versus 2024 (no repeat impairment), but material risks remain: concentrated royalty dependency, unresolved working-capital true-up litigation, substantial accumulated deficit and explicit going-concern uncertainty. Investors should watch Mayne royalty receipts, the outcome of the Mayne lawsuits, any further settlements or one-time income, and capital-raising activity.